Kaur et al. Journal of Diabetes & Metabolic Disorders (2015) 14:80 DOI 10.1186/s40200-015-0212-8



**ERRATUM Open Access** 

## Erratum to: Combined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in rats



Manpreet Kaur, Shilpi Sachdeva, Onkar Bedi, Tavleen Kaur and Puneet Kumar\*

The original version of this article [1] unfortunately contained mistakes to the figure legends and was missing Figure 7 (Fig. 1 here). The corrected legends are as follows:

Fig. 1 Experimental Protocol design.

Fig. 2 Effect of NaHS on blood glucose level in STZ treated rats.  ${}^{a}P < 0.05$  versus vehicle treated,  ${}^{b}P < 0.05$ versus [STZ (45)] treated group,  ${}^{c}P < 0.05$  versus [STZ (45) + NaHS (10)] treated group,  ${}^{d}P < 0.05$  versus [STZ (45) + NaHS (30)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 3 Effect of NaHS and losartan on Lipid Peroxidation in STZ treated rats.  ${}^{a}P < 0.05$  versus vehicle treated,  $^{\rm b}P$  < 0.05 versus [STZ (45)] treated group,  $^{\rm c}P$  < 0.05 versus [STZ (45) + NaHS (10)] treated group,  ${}^{\rm d}P$  < 0.05 versus [STZ (45) + NaHS (30)] treated group,  ${}^{e}P < 0.05$ versus [STZ (45) + LOS (5)] treated group. STZ =Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 4 Effect of NaHS and losartan on Reduced Glutathione in STZ treated rats.  ${}^{a}P < 0.05$  versus vehicle treated,  ${}^{b}P < 0.05$  versus [STZ (45)] treated group,  ${}^{c}P < 0.05$  versus [STZ (45) + NaHS (10)] treated group,  ${}^{d}P < 0.05$  versus [STZ (45) + NaHS (30)] treated group,  ${}^{e}P < 0.05$  versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-propargylglycine.

Fig. 5 Effect of NaHS and losartan on Nitrite in STZ treated rats.  ${}^{a}P < 0.05$  versus vehicle treated,  ${}^{b}P < 0.05$ versus [STZ (45)] treated group,  ${}^{c}P < 0.05$  versus [STZ (45) + NaHS (10)] treated group,  ${}^{d}P < 0.05$  versus [STZ (45) + NaHS (30)] treated group,  ${}^{e}P < 0.05$  versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 6 Effect of NaHS and losartan on MABP in STZ treated rats.  ${}^{a}P < 0.05$  versus vehicle treated,  ${}^{b}P < 0.05$ versus [STZ (45)] treated group, <sup>c</sup>P < 0.05 versus [STZ (45) + NaHS (10)] treated group,  ${}^{d}P < 0.05$  versus [STZ (45) + NaHS (30)] treated group,  ${}^{e}P < 0.05$  versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

<sup>\*</sup> Correspondence: punnubansal79@gmail.com Pharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga 14200, Punjab, India



The missing figure can be found below, with the correct figure legend:




Fig. 1 Hemotoxylin-Eosin stained longitudinal section of kidneys (10×). a Normal control, b STZ treated group (45), c NaHS (30), d DL-p (10) + NaHS (30), e LOS, f NaHS (10) + Losartan (5)

Received: 7 October 2015 Accepted: 8 October 2015 Published online: 22 October 2015

## Reference

 Kaur M, Sachdeva S, Bedi O, Kaur T, Kumar P. Combined effect of hydroden sulphide donor and losartan in experimental diabetic nephropathy in rats. J Diabetes Metab Disord. 2015;14:63. doi:10.1186/s40200-015-0185-7.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

